McKesson (NYSE:MCK) updated its FY20 earnings guidance on Monday. The company provided earnings per share guidance of $14.60-14.80 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $14.38. McKesson also updated its FY 2020
After-Hours guidance to 14.60-14.80 EPS.
A number of research firms have recently weighed in on MCK. TheStreet cut shares of McKesson from a b rating to a c- rating in a research note on Wednesday, October 30th. Morgan Stanley raised shares of McKesson from an equal weight rating to an overweight rating and upped their price target for the stock from $135.00 to $162.00 in a research note on Friday. Finally, UBS Group cut shares of McKesson to a sell rating and set a $147.00 price objective on the stock. in a research note on Thursday. Three analysts have rated the stock with a sell rating, five have assigned a hold rating and three have given a buy rating to the company. The company presently has an average rating of Hold and a consensus price target of $150.78.
Shares of McKesson stock traded down $0.16 during mid-day trading on Monday, hitting $143.65. 936,618 shares of the stock were exchanged, compared to its average volume of 921,864. McKesson has a twelve month low of $110.52 and a twelve month high of $154.79. The stock has a market capitalization of $25.91 billion, a price-to-earnings ratio of 10.59, a price-to-earnings-growth ratio of 1.42 and a beta of 1.12. The company has a 50-day simple moving average of $141.00 and a 200 day simple moving average of $141.39. The company has a current ratio of 1.01, a quick ratio of 0.57 and a debt-to-equity ratio of 1.36.
McKesson (NYSE:MCK) last released its quarterly earnings results on Wednesday, October 30th. The company reported $3.60 earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of $3.60. The company had revenue of $57.62 billion for the quarter, compared to analysts’ expectations of $55.06 billion. McKesson had a negative net margin of 0.29% and a positive return on equity of 32.77%. The firm’s revenue for the quarter was up 8.6% compared to the same quarter last year. During the same period last year, the company earned $3.60 EPS. Equities research analysts forecast that McKesson will post 14.41 earnings per share for the current fiscal year.
The business also recently disclosed a quarterly dividend, which was paid on Thursday, January 2nd. Stockholders of record on Monday, December 2nd were issued a dividend of $0.41 per share. The ex-dividend date of this dividend was Friday, November 29th. This represents a $1.64 annualized dividend and a dividend yield of 1.14%. McKesson’s payout ratio is currently 12.09%.
In other news, EVP Lori A. Schechter sold 1,275 shares of the stock in a transaction dated Thursday, October 17th. The shares were sold at an average price of $150.00, for a total transaction of $191,250.00. Following the transaction, the executive vice president now directly owns 1,275 shares in the company, valued at approximately $191,250. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Corporate insiders own 0.88% of the company’s stock.
McKesson Company Profile
McKesson Corporation provides pharmaceuticals and medical supplies in the United States and internationally. It operates in three segments: U.S. Pharmaceutical and Specialty Solutions, European Pharmaceutical Solutions, and Medical-Surgical Solutions. The company distributes branded, generic, specialty, biosimilar, and over-the-counter pharmaceutical drugs, as well as other healthcare-related products; and offers practice management, technology, clinical support, and business solutions to community-based oncology and other specialty practices.
See Also: Balance Sheet
Receive News & Ratings for McKesson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for McKesson and related companies with MarketBeat.com's FREE daily email newsletter.